[1] Mach F, Baigent C, Catapano AL, et al.2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk[J]. Eur Heart J, 2020, 41(1): 111-188.
[2] 秦瑞丹,张娟,梁营营,等.原发性高血压患者血浆致动脉粥样硬化指数及血清脂蛋白相关磷脂酶A2水平与左心室肥厚的关系研究[J].中国全科医学,2024,27(27):3359-3364.
[3] 刘力生. 中国高血压防治指南2010[J].中华高血压杂志, 2011, 19(8): 701-743.
[4] Pantazi D, Tellis C, Tselepis AD.Oxidized phospholipids and lipoprotein-associated phospholipase A2(Lp-PLA2) in atherosclerotic cardiovascular disease: An update[J]. Biofactors, 2022, 48(6):1257-1270.
[5] 申艳霞. 血清Lp-PLA2、Hcy、CTRP3水平与老年高血压患者冠状动脉病变的相关性及诊断价值[J].中国老年学杂志, 2024, 44(21): 5130-5133.
[6] Hoogeveen RC, Gaubatz JW, Sun W, et al.Small dense low-density lipoprotein-cholesterol concentrations predict risk for coronary heart disease: the Atherosclerosis Risk In Communities (ARIC) study[J]. Arterioscler Thromb Vasc Biol, 2014, 34(5): 1069-1077.
[7] Jin JL, Zhang HW, Cao YX, et al.Association of small dense low-density lipoprotein with cardiovascular outcome in patients with coronary artery disease and diabetes: a prospective, observational cohort study[J]. Cardiovasc Diabetol, 2020, 19(1): 45.
[8] 王雪燕,冯跨,梁志强,等.类风湿关节炎患者NGAL、Lp-PLA2及血脂异常对动脉粥样硬化的预测及在转归中的价值[J].中国老年学杂志, 2020, 40(1): 125-129.
[9] 马青青,赵美英,张晓燕,等.MSCTA联合血清sd-LDL、脂蛋白a检测对冠心病患者的诊断价值[J].临床放射学杂志, 2023, 42(4): 602-605.
[10] 全雪萌,华扬,贾凌云,等.无心脑血管疾病危险因素成年受检者颈动脉管腔结构变化的相关因素分析[J].中国脑血管病杂志, 2024, 21(2): 93-101.
[11] 沈健,张皓然,王枫,等.颈脑一体化超声联合Hcy、hs-CRP对冠状动脉粥样硬化病变程度的评估[J].影像科学与光化学, 2023, 41(1): 96-101.
[12] Gurung AB, Bhattacharjee A.Met117 oxidation leads to enhanced flexibility of cardiovascular biomarker- lipoprotein- associated phospholipase A2 and reduced substrate binding affinity with platelet-activating factor[J]. Int J Biol Macromol. 2018, 112: 831-840. |
